These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 707520)
1. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Mundy GR; Rick ME; Turcotte R; Kowalski MA Am J Med; 1978 Oct; 65(4):600-6. PubMed ID: 707520 [TBL] [Abstract][Full Text] [Related]
2. Adult T-cell leukemia complicated by hypercalcemia. Report of three autopsy cases with special reference to the etiologic factor of hypercalcemia. Haratake J; Ishii N; Horie A; Matsumoto M; Oda S; Satoh K Acta Pathol Jpn; 1985 Mar; 35(2):437-48. PubMed ID: 3875211 [TBL] [Abstract][Full Text] [Related]
3. Effects of glucocorticoids on osteoclast-activating factor. Strumpf M; Kowalski MA; Mundy GR J Lab Clin Med; 1978 Nov; 92(5):772-8. PubMed ID: 712208 [TBL] [Abstract][Full Text] [Related]
4. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor. Josse RG; Murray TM; Mundy GR; Jez D; Heersche JN J Clin Invest; 1981 May; 67(5):1472-81. PubMed ID: 6262378 [TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia and osteoclast proliferation in adult T-cell leukemia. Kiyokawa T; Yamaguchi K; Takeya M; Takahashi K; Watanabe T; Matsumoto T; Lee SY; Takatsuki K Cancer; 1987 Mar; 59(6):1187-91. PubMed ID: 2880656 [TBL] [Abstract][Full Text] [Related]
6. Humoral hypercalcemia of malignancy. Release of a prostaglandin-stimulating bone-resorbing factor in vitro by human transitional-cell carcinoma cells. Bringhurst FR; Bierer BE; Godeau F; Neyhard N; Varner V; Segre GV J Clin Invest; 1986 Feb; 77(2):456-64. PubMed ID: 3003159 [TBL] [Abstract][Full Text] [Related]
7. Production of bone-resorbing activity and colony-stimulating activity in vivo and in vitro by a human squamous cell carcinoma associated with hypercalcemia and leukocytosis. Sato K; Mimura H; Han DC; Kakiuchi T; Ueyama Y; Ohkawa H; Okabe T; Kondo Y; Ohsawa N; Tsushima T J Clin Invest; 1986 Jul; 78(1):145-54. PubMed ID: 3487554 [TBL] [Abstract][Full Text] [Related]
8. Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes. Luben RA; Mundy GR; Trummel CL; Raisz LG J Clin Invest; 1974 May; 53(5):1473-80. PubMed ID: 4825237 [TBL] [Abstract][Full Text] [Related]
9. [Hypercalcemia and osteoclast activating factor (OAF) associated with acute lymphoblastic leukemia (author's transl)]. Durocher A; Ballet JJ; Pirot J; Granier F; Bauters F; Wattel F Sem Hop; 1979 May 18-25; 55(19-20):1008-10. PubMed ID: 227085 [TBL] [Abstract][Full Text] [Related]
11. Bone resorption by isolated chick osteoclasts in culture is stimulated by murine spleen cell supernatant fluids (osteoclast-activating factor) and inhibited by calcitonin and prostaglandin E2. de Vernejoul MC; Horowitz M; Demignon J; Neff L; Baron R J Bone Miner Res; 1988 Feb; 3(1):69-80. PubMed ID: 3264994 [TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones. Tobias J; Chambers TJ Endocrinology; 1989 Sep; 125(3):1290-5. PubMed ID: 2759026 [TBL] [Abstract][Full Text] [Related]
13. Evidence of bone resorption-stimulating factor in adult T-cell leukemia. Fujihira T; Eto S; Sato K; Zeki K; Oda S; Chiba S; Suzuki H Jpn J Clin Oncol; 1985 Jun; 15(2):385-91. PubMed ID: 3874974 [TBL] [Abstract][Full Text] [Related]
14. Identification of 1,24(R)-dihydroxyvitamin D3-like bone-resorbing lipid in a patient with cancer-associated hypercalcemia. Shigeno C; Yamamoto I; Dokoh S; Hino M; Aoki J; Yamada K; Morita R; Kameyama M; Torizuka K J Clin Endocrinol Metab; 1985 Oct; 61(4):761-8. PubMed ID: 2993347 [TBL] [Abstract][Full Text] [Related]
15. EGF receptor antiserum inhibits bone resorbing activity produced by a rat Leydig cell tumor associated with the humoral hypercalcemia of malignancy. Ibbotson KJ; D'Souza SM; Smith DD; Carpenter G; Mundy GR Endocrinology; 1985 Jan; 116(1):469-71. PubMed ID: 2981075 [TBL] [Abstract][Full Text] [Related]
16. Ascites sarcoma 180, an animal model of humoral hypercalcemia of malignancy, produces a factor(s) exhibiting potent bone-resorbing activity without any parathyroid hormone-like activity. Suzuki K; Yamada S Bone Miner; 1991 Jul; 14(1):1-13. PubMed ID: 1651137 [TBL] [Abstract][Full Text] [Related]
17. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts. Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680 [TBL] [Abstract][Full Text] [Related]
18. Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia. Sato K; Fujii Y; Kasono K; Tsushima T; Shizume K J Clin Endocrinol Metab; 1988 Sep; 67(3):592-601. PubMed ID: 3261732 [TBL] [Abstract][Full Text] [Related]
19. Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. Yoneda T; Mundy GR J Exp Med; 1979 Aug; 150(2):338-50. PubMed ID: 458377 [TBL] [Abstract][Full Text] [Related]
20. Failure of parathyroid hormone antagonists to inhibit in vitro bone resorbing activity produced by two animal models of the humoral hypercalcemia of malignancy. D'Souza SM; Ibbotson KJ; Mundy GR J Clin Invest; 1984 Sep; 74(3):1104-7. PubMed ID: 6470137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]